CStone Reports CS2009 Clinical Validation, Plans Phase III Trials
CStone said CS2009 achieved proof of mechanism, safety and concept based on data from more than 300 patients across solid tumors, including NSCLC and mCRC. The company is preparing global Phase III registrational trials and discussing partnerships.